LOS ANGELES (MarketWatch) -- Chinese police are recommending prosecution for alleged bribery by U.K. pharmaceutical firm GlaxoSmithKline PLC GSK, +0.31% GSK, -0.53% , China's state-run Xinhua News Agency reported Wednesday. GSK executive William Mark Reilly is believed by law enforcement to have ordered his sales teams to bribe hospitals, doctors and health institutions to gain "illegal revenue worth ... billions" of yuan, the report said. Police in Changsha, the capital of China's southeastern province of Henan, handed the case to prosecutors following a 10 month investigation, it said. Two other GSK executives, Zhang Guowei and Zhao Hongyan, were also suspected of bribing officials in Beijing and Shanghai, according to Xinhua.